

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-32 (cancelled).

31. (Currently Amended) An agonist antibody, or a binding fragment thereof, that specifically binds to or interacts with the extracellular domain of human G-CSF receptor to stimulate cell proliferation and differentiation.
32. (Previously Presented) The agonist antibody, or binding fragment thereof, of claim 31, which dimerizes the receptor or activates phosphorylation of kinases associated with the receptor to stimulate cell proliferation and differentiation.
33. (Previously Presented) The agonist antibody or binding fragment of claim 31 or 32, which stimulates proliferation and differentiation of neutrophils or their progenitor cells.
34. Cancelled.
35. Cancelled.
36. (Previously Presented) The agonist antibody or binding fragment of claim 31 or 32, wherein the antibody interacts at an epitope between amino acid residues 1-603 (SEQ ID NO:27) of the G-CSF receptor.
37. (Previously Presented) The agonist antibody or binding fragment of claim 31 or 32, wherein said antibody is a monoclonal antibody.
38. (Previously Presented) The agonist antibody or binding fragment of claim 31 or 32, wherein the fragment is Fab, F(ab), F(ab'), F(ab')₂, Fd, Fv, or single chain antibody.
39. (Previously Presented) The agonist antibody of claim 37, wherein the antibody is mAb163-93 or mAb174-74-11, which are produced by the hybridoma cell lines deposited at the ATCC, Manassas, Virginia, under Accession Nos. HB 12699 and HB 12700, respectively.

40. (Previously Presented) A cell line that produces the agonist antibody or binding fragment of claim 31.
41. (Previously Presented) A hybridoma cell line wherein the cell line is HB-12699 or HB-12700 as deposited with the ATCC, Manassas, Virginia.
42. Cancelled.
43. Cancelled.
44. Withdrawn.
45. (Previously Presented) A composition comprising at least one agonist antibody according to claim 31 or 32, and a physiologically acceptable carrier, diluent, and/or excipient.
46. Withdrawn.
47. Withdrawn.
48. (NEW) An agonist antibody, or binding fragment thereof, that specifically binds to or interacts with human G-CSF receptor wherein the human G-CSF receptor used to generate said antibody is a native human G-CSF receptor or a mutant thereof comprising substitutions, insertions, or deletions.
49. (NEW) The agonist antibody of claim 31, wherein the antibody comprises SEQ ID NO: 15 to SEQ ID NO 20, or a functional variant of any one of SEQ ID Nos 15 to 20.
50. (NEW) The agonist antibody of claim 48, wherein the framework is human or humanized.